Axovant Sciences (NASDAQ:AXON) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “
A number of other research analysts have also recently issued reports on the company. Cowen reissued a “hold” rating on shares of Axovant Sciences in a report on Tuesday. Oppenheimer reissued a “hold” rating on shares of Axovant Sciences in a report on Tuesday. ValuEngine raised Axovant Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Chardan Capital raised Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 price objective for the company in a report on Wednesday, January 10th. Finally, Jefferies Group cut Axovant Sciences from a “buy” rating to a “hold” rating and set a $6.00 price objective for the company. in a report on Thursday, December 21st. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $13.61.
Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its stake in shares of Axovant Sciences by 99.8% in the fourth quarter. BlackRock Inc. now owns 2,912,219 shares of the biotechnology company’s stock valued at $15,347,000 after buying an additional 1,454,454 shares in the last quarter. OxFORD Asset Management LLP increased its stake in shares of Axovant Sciences by 842.1% in the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after buying an additional 777,505 shares in the last quarter. Eagle Asset Management Inc. acquired a new stake in shares of Axovant Sciences in the third quarter valued at $4,471,000. Hudson Bay Capital Management LP acquired a new stake in shares of Axovant Sciences in the fourth quarter valued at $1,845,000. Finally, Artal Group S.A. increased its stake in shares of Axovant Sciences by 185.7% in the third quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock valued at $3,440,000 after buying an additional 325,000 shares in the last quarter. 96.82% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Axovant Sciences (AXON) Downgraded by Zacks Investment Research to “Hold”” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/14/axovant-sciences-axon-downgraded-by-zacks-investment-research-to-hold.html.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.